AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or More.

Socinski MA, Reck M, Paz-Ares L, Nishio M, Spira AI, Yu X, Melkadze T, Zeng A, Martinez-Bueno A, Li X, Arulananda S, Zuo Y, Chica-Duque S, Dai W, Zhou J, Tan W, Lu S

Open source

DOI: 10.1016/j.jtho.2026.104089
Published: 2026 Jul 14
Container: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2026.104089,
  title = {AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50\% or More.},
  author = {Socinski MA and Reck M and Paz-Ares L and Nishio M and Spira AI and Yu X and Melkadze T and Zeng A and Martinez-Bueno A and Li X and Arulananda S and Zuo Y and Chica-Duque S and Dai W and Zhou J and Tan W and Lu S},
  year = {2026},
  journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  doi = {10.1016/j.jtho.2026.104089},
  url = {https://doi.org/10.1016/j.jtho.2026.104089}
}

RIS

TY  - JOUR
TI  - AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or More.
AU  - Socinski MA
AU  - Reck M
AU  - Paz-Ares L
AU  - Nishio M
AU  - Spira AI
AU  - Yu X
AU  - Melkadze T
AU  - Zeng A
AU  - Martinez-Bueno A
AU  - Li X
AU  - Arulananda S
AU  - Zuo Y
AU  - Chica-Duque S
AU  - Dai W
AU  - Zhou J
AU  - Tan W
AU  - Lu S
PY  - 2026
JO  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DO  - 10.1016/j.jtho.2026.104089
UR  - https://doi.org/10.1016/j.jtho.2026.104089
ER  -

APA

MA, S., M, R., L, P., M, N., AI, S., X, Y., T, M., A, Z., A, M., X, L., S, A., Y, Z., S, C., W, D., J, Z., W, T., & S, L. (2026). AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or More.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2026.104089

Source records

pubmed · retrieved 2026-09-25T23:23:31.702Z